Skip to main content
SpringerLink
Log in

Fortgeschrittenes Nierenzellkarzinom

Langes progressionsfreies Überleben unter Lenvatinib plus Pembrolizumab

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Motzer R et al. N Engl J Med. 2021;384(14):1289-300

  2. Choueiri TK et al. N Engl J Med. 2021;384(9):829-41

  3. Choueiri TK et al. Ann Oncol. 2020;31(8):1030-9

  4. Powles T et al. Lancet Oncol. 2020;21(12):1563-73

  5. Motzer RJ et al. N Engl J Med. 2018;378(14):1277-90

  6. Ravaud A. N Engl J Med. 2021;384(14):1360-1

  7. https://www.onkopedia.com/de/onkopedia/guidelines/nierenzellkarzinom-hypernephrom, abgerufen am 15. April 2021

Download references

Author information

Authors and Affiliations

  1. FA für Onkologie, Lena-Christ-Str. 17, 82152, Planegg, Deutschland

    Andreas Schalhorn

Authors
  1. Andreas Schalhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Schalhorn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schalhorn, A. Langes progressionsfreies Überleben unter Lenvatinib plus Pembrolizumab. InFo Hämatol Onkol 24, 26–27 (2021). https://doi.org/10.1007/s15004-021-8663-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8663-1

Search

Navigation